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1. Acute exacerbations of chronic bronchitis - the role of moxifloxacin and 
other new fluoroquinolones 
A. ANZUETO AND G. TILLOTSON” 
Audie Murphy VA Hosp, San Antonio, Texas and “Bayer Corporation, West Haven CT., US.A. 
In recent years, extensive efforts have been made to develop new fluoroquinolones with improved activities against Gram- 
positive organisms, such as S. pneumoniue. The role of moxifloxacin, an 8-methoxyquinolone, for the treatment of acute 
bacterial exacerbations of chronic bronchitis (AECB) is reviewed. Moxifloxacin is highly active against H in&enzae, the most 
common pathogen associated with AECB, and shows excellent in vitro activity against the other major pathogens, M. 
catarrhalis, S. pneumoniae, and minor pathogens. Moxifloxacin’s in vitro antibacterial activity against Gram-positive bacteria 
is significantly better than that of ciprofloxacin, levofloxacin or sparfloxacin. In comparative trials involving commonly used 
treatment regimens, moxifloxacin (400mg daily for 5d) achieved bacteriologic and/or clinical success rates of approximately 
90% or higher. Moxifloxacin had a higher eradication rate for the four most commonly isolated pathogens (95%) compared to 
clarithromycin and cefuroxime (87% and 83% respectively). The clinical success rate of moxifloxacin 400mg daily for 5 days 
(93O%) was identical to that of the comparator, co-amoxiclav, three times daily for 7 days (91%). Fluoroquinolones have a good 
clinical success rate in the treatment of AECB, but are rarely considered first-line agents because of perceived low efficacy 
against S. pneumoniae. With its good tissue penetration, safety profile and excellent activity against all common respiratory 
pathogens, moxifloxacin is an effective, safe and well tolerated option in the treatment of acute exacerbations of chronic 
bronchitis. Moxifloxacin carries the advantage of once-daily dosing and short treatment duration (5 days). 
2. Epidemiological variables within a protocol of surveillance anti-TBC toward 
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Preventing TBC is still a compulsory goal in all countries but guidelines are not easy to follow because of many social, 
individual and legal obstacles also rising from people’s mobility. For over 10 years we have been carrying out an epidemio- 
logical surveillance anti-tubercular programme to study the immunitary condition toward Koch’s bacillus in the population 
represented by social-healthy operators. The idea about this study comes out from the observation of the various kind of 
healthy operators working in our Institute and from the consideration that most of these figures are not common in other 
ones. We studied 745 subjects, employed in our Institute from 1996 to 1999. Mostly the Mantoux’ s intradermo reaction- 
negative (IDR Mtx) operators refused the anti-tubercular vaccination (as shown in the following table). We think that the 
different,kind of answers to proposal of the antitubercular vaccination depends on some variables: 
(1) knowledge about the pathology; 
(2) cultural level; 
(3) civic conscience about general health; 
(4) title of the study; 
(5) temporary work that does not permit subjects to be followed with time. 
Our data show many difficulties preventing the achiement of an effective anti-tubercular surveillance program. 
3. Cefodizime enhances phagocytosis and intracellular killing of Staphylococcus 
aweus but does not influence polymorphonuclear leukocytes response 
to FMLP stimulation 
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Polymorphonuclear leukocytes (PMNL) are key defence cells against bacterial and fungal infections. Cefodizime (CDZ) - an 
aminothiazolylcephalosporin - has been reported to favourably influence immunodefense in chronic diseases (eg. diabetes, 
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